Ocumetics Technology: Pioneering Vision Enhancement with the Ocumetics Accommodating Lens

Ocumetics Technology Corp. (TSXV:OTC, OTCQB:OTCFF, FRA:2QBO) focuses on a groundbreaking vision enhancement product - the Ocumetics Accommodating Lens. Leading the forefront of research and product development, Ocumetic's intraocular lens (IOL) is engineered to seamlessly shift the eye's focus from close to far distances without any noticeable lag. This process is called accommodation.

The eye's natural lens loses its flexibility to bend light rays accurately due to aging and injuries. This leads to the deterioration of eyesight and potential conditions like cataracts with or without astigmatism. Ocumetics has designed a very unique IOL that is surgically implanted to restore a patient’s vision. This lens is designed to harmoniously align with the eye's natural mechanisms, enhancing vision by appropriately bending light rays. Notably, it's designed to last a lifetime, presenting a significant potential advancement over other cataract technologies.

Ocumetics aims to solve the problem of eyesight degradation. The proposed solution is a surgically implanted lens that takes over the function of properly bending rays of light by working with the eye’s natural mechanisms, resulting in enhanced vision. Following a series of product enhancements, development of surgical procedure protocols, and animal testing for biocompatibility, the Ocumetics Accommodating Lens will soon begin human trials as the company works toward bringing the product to market.

Company Highlights

• Ocumetics Technology Corp. is an R&D company developing a vision enhancement product with the potential to disrupt the vision correction industry.
• The Ocumetics Accommodating Lens is an intraocular lens designed to allow the human eye to shift between close and long-distance images without perceptible adjustment lag.
• Ocumetics’ product is surgically implanted and is designed to enhance the natural processes, allowing the patient’s eyes to bend light properly for better vision.
• The Ocumetics Accommodating Lens has substantially completed a series of design improvements, animal studies, surgical procedure development and biocompatibility studies and will soon move toward human clinical trials, slated to begin in Q1 2024.
• The company aims to receive full US FDA approval within three-and-a-half years and bring its product to a projected intraocular lens market segment of US$6.4 billion by 2030 (Delveinsight 2022).
• An expert team with experience in clinical eye care, R&D and corporate development is leading the company toward bringing its transformative product to market.

This Ocumetics Technology profile is part of a paid investor education campaign.*

Click here to connect with Ocumetics Technology Corp. (TSXV:OTC, OTCQB:OTCFF, FRA:2QBO) to receive an Investor Presentation